Phase II study of high-sensitivity genotyping of KRAS , NRAS , BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. - Santos, C; Azuara, D; Viéitez, J M; Páez, D; Falcó, E; Élez, E; López-López, C; Valladares, M; Robles-Díaz, L; García-Alfonso, P; Bugés, C; Durán, G; et al. (Annals of Oncology, 2019)